All In Biotech

Drug Trial Radar · NCT03605667

Study of BHV-4157 in Alzheimer's Disease

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Jul 31, 2018

Primary completion

Dec 15, 2020

Study completion Dec 23, 2021

Sponsor

Lead sponsor
Biohaven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)
First posted
Jul 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily. Duration of treatment is 48 weeks in double-blind phase. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period. Eligible participants who completed the double-blind treatment phase had the opportunity to receive open-label troriluzole for up to 48 weeks in an open-label extension (OLE) phase.

Conditions

  • Alzheimer Disease

Interventions

  • troriluzoleDrug

    Oral BHV-4157 will be given daily for up to 48 weeks

  • Placebo oral capsuleDrug

    Oral matching placebo will be given daily for up to 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 48Time frame: Baseline (Day 1) and Week 48
  2. Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-Sum of Boxes) Total Score at Week 48Time frame: Baseline (Day 1) and Week 48

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Xenoscience, Inc.

    Phoenix, Arizona

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • University of California, San Diego

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • SC3 Research Group - Pasadena

    Pasadena, California

  • Geriatric and Adult Psychiatry

    Hamden, Connecticut

  • Yale University School of Medicine

    New Haven, Connecticut

  • Ki Health PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH

    Stamford, Connecticut

  • Brain Matters Research

    Delray Beach, Florida

  • University of Miami

    Miami, Florida

  • USF Health Byrd Alzheimer's Institute

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Southern Illinois University

    Springfield, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Northern Light Acadia Hospital

    Bangor, Maine

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Michigan, Ann Arbor

    Ann Arbor, Michigan

  • Michigan State University

    East Lansing, Michigan

  • Galen Research

    Chesterfield, Missouri

  • Cleveland Clinic Lou Ruvo Center

    Las Vegas, Nevada

  • Princeton Medical Institute

    Princeton, New Jersey

  • Columbia University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • SUNY Upstate Medical University Department of Geriatrics

    Syracuse, New York

  • James J. Peters VAMC

    The Bronx, New York

  • Case Western Reserve University

    Beachwood, Ohio

  • Ohio State University

    Columbus, Ohio

  • Tulsa Clinical Research

    Tulsa, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Keystone Clinical Studies, LLC

    Norristown, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Geisinger Medical Clinic

    Wilkes-Barre, Pennsylvania

  • Abington Neurological Associates

    Willow Grove, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.